These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 23161490)
21. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen. Rice J; Buchan S; Stevenson FK J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189 [TBL] [Abstract][Full Text] [Related]
22. Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes. Smith CC; Chai S; Washington AR; Lee SJ; Landoni E; Field K; Garness J; Bixby LM; Selitsky SR; Parker JS; Savoldo B; Serody JS; Vincent BG Cancer Immunol Res; 2019 Oct; 7(10):1591-1604. PubMed ID: 31515258 [TBL] [Abstract][Full Text] [Related]
23. Anti-tumor immune responses and tumor regression induced with mimotopes of a tumor-associated T cell epitope. Tumenjargal S; Gellrich S; Linnemann T; Muche JM; Lukowsky A; Audring H; Wiesmüller KH; Sterry W; Walden P Eur J Immunol; 2003 Nov; 33(11):3175-85. PubMed ID: 14579286 [TBL] [Abstract][Full Text] [Related]
24. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs. Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753 [TBL] [Abstract][Full Text] [Related]
25. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186 [TBL] [Abstract][Full Text] [Related]
26. A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity. Walters JN; Ferraro B; Duperret EK; Kraynyak KA; Chu J; Saint-Fleur A; Yan J; Levitsky H; Khan AS; Sardesai NY; Weiner DB Mol Ther; 2017 Apr; 25(4):976-988. PubMed ID: 28237837 [TBL] [Abstract][Full Text] [Related]
27. An In Vivo Screen to Identify Short Peptide Mimotopes with Enhanced Antitumor Immunogenicity. He X; Zhou S; Quinn B; Jahagirdar D; Ortega J; Long MD; Abrams SI; Lovell JF Cancer Immunol Res; 2022 Mar; 10(3):314-326. PubMed ID: 34992135 [TBL] [Abstract][Full Text] [Related]
28. Cancer immunotherapy by a recombinant phage vaccine displaying EGFR mimotope: an in vivo study. Asadi-Ghalehni M; Ghaemmaghami M; Klimka A; Javanmardi M; Navari M; Rasaee MJ Immunopharmacol Immunotoxicol; 2015 Jun; 37(3):274-9. PubMed ID: 25990849 [TBL] [Abstract][Full Text] [Related]
29. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. Casares N; Arribillaga L; Sarobe P; Dotor J; Lopez-Diaz de Cerio A; Melero I; Prieto J; Borrás-Cuesta F; Lasarte JJ J Immunol; 2003 Dec; 171(11):5931-9. PubMed ID: 14634104 [TBL] [Abstract][Full Text] [Related]
30. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. Riemer AB; Förster-Waldl E; Brämswig KH; Pollak A; Zielinski CC; Pehamberger H; Lode HN; Scheiner O; Jensen-Jarolim E Eur J Immunol; 2006 May; 36(5):1267-74. PubMed ID: 16568495 [TBL] [Abstract][Full Text] [Related]
31. Melanoma vaccines: the paradox of T cell activation without clinical response. Nielsen MB; Marincola FM Cancer Chemother Pharmacol; 2000; 46 Suppl():S62-6. PubMed ID: 10950150 [TBL] [Abstract][Full Text] [Related]
35. Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells. Wierzbicki A; Gil M; Ciesielski M; Fenstermaker RA; Kaneko Y; Rokita H; Lau JT; Kozbor D J Immunol; 2008 Nov; 181(9):6644-53. PubMed ID: 18941255 [TBL] [Abstract][Full Text] [Related]
36. Mimotope vaccines for cancer immunotherapy. Sharav T; Wiesmüller KH; Walden P Vaccine; 2007 Apr; 25(16):3032-7. PubMed ID: 17276556 [TBL] [Abstract][Full Text] [Related]
37. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy. Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273 [TBL] [Abstract][Full Text] [Related]
38. Immunogene therapy. Lichtor T; Glick RP Adv Exp Med Biol; 2012; 746():151-65. PubMed ID: 22639166 [TBL] [Abstract][Full Text] [Related]
39. Vaccine therapy of established tumors in the absence of autoimmunity. Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742 [TBL] [Abstract][Full Text] [Related]
40. In Silico-Guided Sequence Modification of Epitopes in Cancer Vaccine Development. Hoo WPY; Siak PY; In LLA Methods Mol Biol; 2020; 2131():213-228. PubMed ID: 32162256 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]